Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Deals

CStone Pharmaceuticals and SteinCares Ink Licensing Deal for PD-L1 Inhibitor in Latin America

Fineline Cube Mar 6, 2025

China-based CStone Pharmaceuticals (HKG: 2616) and Costa Rica-based drug maker and distributor SteinCares have entered...

Company Drug

Fosun Pharma’s 24-Valent Pneumococcal Vaccine Receives NMPA Approval for Phase I Trial

Fineline Cube Mar 6, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Adgenvax (Chengdu)...

Company Deals

Bio-Thera Solutions Inks Licensing Deal with World Medicine for BAT2206

Fineline Cube Mar 5, 2025

China-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with World Medicine, granting...

Company Deals

Hainan Poly Pharm’s US Partner Slate Run Pharmaceuticals Collaborates with Premier on Contrast Agents

Fineline Cube Mar 5, 2025

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced a significant partnership between its US...

Company Deals

Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies

Fineline Cube Mar 5, 2025

US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement...

Company

MSD China Reorganizes to Boost Mature Product Lines

Fineline Cube Mar 5, 2025

Anna Van Acker, Senior Vice-President of Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and...

Company Drug

Suzhou Abogen’s RSV mRNA Vaccine IND Approved by China’s CDE

Fineline Cube Mar 5, 2025

China-based nucleic acid drug developer Suzhou Abogen Biosciences announced that the Investigational New Drug (IND)...

Policy / Regulatory

CDE Launches SPARK Project to Boost Pediatric Antitumor Drug R&D

Fineline Cube Mar 5, 2025

China’s Center for Drug Evaluation (CDE) has released a notification to solicit feedback on its...

Company Drug

BeiGene’s Tevimbra Receives FDA Approval for ESCC Treatment

Fineline Cube Mar 5, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a multinational oncology company planning to change...

Company

Organon’s 2024 Financial Report Shows Steady Growth in Women’s Health and Biosimilars

Fineline Cube Mar 4, 2025

Women’s health specialist Organon (NYSE: OGN) released its 2024 financial report, showing a 3% year-on-year...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Shows Positive Results in Phase III Study

Fineline Cube Mar 4, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced positive topline results from the...

Company

Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents

Fineline Cube Mar 4, 2025

The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding...

Company Drug

Genentech’s TNKase Approved by FDA for Acute Ischemic Stroke Treatment

Fineline Cube Mar 4, 2025

Genentech, a subsidiary of Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), announced that its thrombolytic...

Company Drug

Eisai’s Lecanemab Rejected by Australia’s TGA for Early Alzheimer’s Treatment

Fineline Cube Mar 4, 2025

Japan-based Eisai Co., Ltd (TYO: 4523) announced that the Therapeutic Goods Administration (TGA) of Australia...

Company Deals Medical Device

Boston Scientific to Acquire SoniVie, Boosting Hypertension Treatment Portfolio

Fineline Cube Mar 4, 2025

Boston Scientific Corporation (NYSE: BSX) is set to acquire SoniVie Ltd, an Israel-based medical device...

Company Drug

Fapon Biopharma’s FP008 Receives FDA Approval for Clinical Trials

Fineline Cube Mar 4, 2025

China-based Fapon Biopharma announced that it has received clinical trial approval from the US Food...

Company Deals

Kyorin Pharmaceutical Licenses KRP-M223 to Novartis for Global Development

Fineline Cube Mar 4, 2025

Japan-based Kyorin Pharmaceutical Co., Ltd. announced a licensing agreement with Novartis (NYSE: NVS), granting the...

Company Drug

GSK’s Depemokimab Accepted for FDA Review as Ultra-Long-Acting Biologic

Fineline Cube Mar 4, 2025

GSK plc (LON: GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA)...

Company Drug

Juvestar and Raziel Therapeutics Launch Phase III Study for RZL-012 in China

Fineline Cube Mar 4, 2025

Juvestar Biotech Co., Ltd., a subsidiary of China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:...

Company Medical Device

Waters and Kehua’s LC-MS Systems Gain NMPA Approval for IVD Use

Fineline Cube Mar 4, 2025

Two home-grown liquid chromatography with tandem mass spectrometry (LC-MS) systems, the ACQUITY UPLC I-Class PLUS...

Posts pagination

1 … 245 246 247 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.